94 related articles for article (PubMed ID: 10675753)
1. Isolation and characterization of human multiple myeloma cell enriched populations.
Tai YT; Teoh G; Shima Y; Chauhan D; Treon SP; Raje N; Hideshima T; Davies FE; Anderson KC
J Immunol Methods; 2000 Feb; 235(1-2):11-9. PubMed ID: 10675753
[TBL] [Abstract][Full Text] [Related]
2. The efficiency of tumor cell purging using immunomagnetic CD34+ cell separation systems.
Roots-Weiss A; Papadimitriou C; Serve H; Hoppe B; Koenigsmann M; Reufi B; Oberberg D; Thiel E; Berdel WE
Bone Marrow Transplant; 1997 Jun; 19(12):1239-46. PubMed ID: 9208119
[TBL] [Abstract][Full Text] [Related]
3. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
Kara IO; Sahin B; Paydas S; Cetiner S
Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
[TBL] [Abstract][Full Text] [Related]
4. Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation.
Borset M; Helseth E; Naume B; Waage A
Br J Haematol; 1993 Nov; 85(3):446-51. PubMed ID: 8136264
[TBL] [Abstract][Full Text] [Related]
5. A negative-selection strategy for depleting myeloma cells from patients' BM and/or leukapheresis blood.
Louis SA; Zapf R; Clarke E; Thomas TE; Sutherland HJ
Cytotherapy; 2001; 3(6):489-504. PubMed ID: 11953033
[TBL] [Abstract][Full Text] [Related]
6. Isolation of bone marrow plasma cells by negative selection with immunomagnetic beads.
Fillola G; Muller C; Bousquet R; Fontanilles AM; Laharrague P; Corberand JX
J Immunol Methods; 1996 Mar; 190(1):127-31. PubMed ID: 8601705
[TBL] [Abstract][Full Text] [Related]
7. Elimination of malignant tumor cells from human bone marrow using monoclonal antibodies and immunomagnetic beads.
Wang SY; Makl KL; Chen LY; Tzeng CH; Hu CP; Chang C
Anticancer Res; 1993; 13(6A):2281-5. PubMed ID: 8297147
[TBL] [Abstract][Full Text] [Related]
8. Response patterns of purified myeloma cells to hematopoietic growth factors.
Anderson KC; Jones RM; Morimoto C; Leavitt P; Barut BA
Blood; 1989 May; 73(7):1915-24. PubMed ID: 2713508
[TBL] [Abstract][Full Text] [Related]
9. [Significance of CD138/syndecan-1 for multiple myeloma immunophenotypes].
Zhuang JL; Wang X; Wu YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec; 13(6):1023-7. PubMed ID: 16403272
[TBL] [Abstract][Full Text] [Related]
10. Isolation of human bone marrow mesenchymal stem cells using different membrane markers: comparison of colony/cloning efficiency, differentiation potential, and molecular profile.
Kastrinaki MC; Andreakou I; Charbord P; Papadaki HA
Tissue Eng Part C Methods; 2008 Dec; 14(4):333-9. PubMed ID: 18800875
[TBL] [Abstract][Full Text] [Related]
11. Immunomagnetic detection and clinical significance of micrometastatic tumor cells in malignant melanoma patients.
Faye RS; Aamdal S; Høifødt HK; Jacobsen E; Holstad L; Skovlund E; Fodstad Ø
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4134-9. PubMed ID: 15217950
[TBL] [Abstract][Full Text] [Related]
12. The effect of recombinant human interleukin-3 and recombinant human granulocyte-macrophage colony-stimulating factor on Fc gamma receptor expression and antibody-dependent cellular cytotoxicity of hematopoietic progenitor cells during in vitro myeloid maturation.
Ericson SG; Benoit NE; Mills LE; Fanger MW
Exp Hematol; 1994 Mar; 22(3):283-9. PubMed ID: 7509291
[TBL] [Abstract][Full Text] [Related]
13. CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells.
Kim D; Park CY; Medeiros BC; Weissman IL
Leukemia; 2012 Dec; 26(12):2530-7. PubMed ID: 22733078
[TBL] [Abstract][Full Text] [Related]
14.
Bolzoni M; Ronchetti D; Storti P; Donofrio G; Marchica V; Costa F; Agnelli L; Toscani D; Vescovini R; Todoerti K; Bonomini S; Sammarelli G; Vecchi A; Guasco D; Accardi F; Palma BD; Gamberi B; Ferrari C; Neri A; Aversa F; Giuliani N
Haematologica; 2017 Apr; 102(4):773-784. PubMed ID: 28057743
[TBL] [Abstract][Full Text] [Related]
15. The phenotype of freshly isolated and cultured human bone marrow allostimulatory cells: possible heterogeneity in bone marrow dendritic cell populations.
Egner W; Hart DN
Immunology; 1995 Aug; 85(4):611-20. PubMed ID: 7558157
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell culture: a simple closed culture system using ficoll, monocytes, and a table-top centrifuge.
Celluzzi CM; Welbon C
J Hematother Stem Cell Res; 2003 Oct; 12(5):575-85. PubMed ID: 14594514
[TBL] [Abstract][Full Text] [Related]
17. RANK Expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone.
Atkins GJ; Kostakis P; Vincent C; Farrugia AN; Houchins JP; Findlay DM; Evdokiou A; Zannettino AC
J Bone Miner Res; 2006 Sep; 21(9):1339-49. PubMed ID: 16939392
[TBL] [Abstract][Full Text] [Related]
18. Diverse niches within multiple myeloma bone marrow aspirates affect plasma cell enumeration.
Nadav L; Katz BZ; Baron S; Yossipov L; Polliack A; Deutsch V; Geiger B; Naparstek E
Br J Haematol; 2006 Jun; 133(5):530-2. PubMed ID: 16681641
[TBL] [Abstract][Full Text] [Related]
19. An increase in MPC-1- and MPC-1-CD45+ immature myeloma cells in the progressive states of bone marrow plasmacytosis: the revised phenotypic classification of monoclonal marrow plasmacytosis (MOMP-2005).
Otsuyama K; Asaoku H; Kawano MM
Int J Hematol; 2006 Jan; 83(1):39-43. PubMed ID: 16443550
[TBL] [Abstract][Full Text] [Related]
20. Human blood dendritic cell-like B cells isolated by the 5G9 monoclonal antibody reactive with a novel 220-kDa antigen.
Zhong RK; Donnenberg AD; Zhang HF; Watkins S; Zhou JH; Ball ED
J Immunol; 1999 Aug; 163(3):1354-62. PubMed ID: 10415035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
